Publications

Export 12869 results:
Sort by: Author [ Title  (Desc)] Type Year
A B C D E F [G] H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
V
J.J.A. v.d. Dungen, O. Gabriel, W. Soliman, and C. S. D. R. and Engeln., "VUV-LIF spectroscopy of Ro-vibrationally excited HD molecules produced in hydrogen-deuterium plasmas", 10th EUREGIONAL WELTPP, Workshop on the Exploration of Low Temperature Plasma Physics, Kerkrade, The Netherlands, The Netherland, 2007.
El-Dakrouri, A., J. Yan, M. C. Gupta, M. Laroussi, and Y. Badr, "VUV emission from a novel DBD-based radiation source", Journal of Physics D: Applied Physics, vol. 35, no. 21, pp. L109-L114, 2002. AbstractWebsite
n/a
El‑Shahat, S., A. M. El‑Zafarany, T. A. B. O. U. E. L. SEOUD, and S. A. Ghoniem, "Vulnerability assessment of African coasts to sea level rise using GIS and remote sensing", Environment, Development and Sustainability, vol. 23, issue 2, pp. 2827-2845, 2021.
HM, Y., K. E, K. R, A. AM, P. N, F. A, S. S, T. A, R. T, G. G, et al., "VRS2 regulates hormone-mediated inflorescence patterning in barley", Nature Genetics, 2017. ng.3717.pdf
Howard, J., K. I. Ataga, R. C. Brown, M. Achebe, V. Nduba, A. El-Beshlawy, H. Hassab, I. Agodoa, M. Tonda, S. Gray, et al., "Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.", The Lancet. Haematology, vol. 8, issue 5, pp. e323-e333, 2021. Abstract

BACKGROUND: For decades, patients with sickle cell disease have had only a limited number of therapies available. In 2019, voxelotor (1500 mg), an oral once-daily sickle haemoglobin polymerisation inhibitor, was approved in the USA for the treatment of sickle cell disease in patients aged 12 years and older on the basis of HOPE trial data. To further describe the applicability of voxelotor as a treatment for this chronic illness, we report the long-term efficacy and safety of this drug at 72 weeks of treatment; the conclusion of the placebo-controlled HOPE trial.

METHODS: HOPE is an international, randomised, double-blind, placebo-controlled, phase 3 trial done at 60 clinical sites in Canada, Egypt, France, Italy, Jamaica, Kenya, Lebanon, Netherlands, Oman, Turkey, the USA, and the UK. Patients (aged 12-65 years) with confirmed sickle cell disease, a haemoglobin concentration of 5·5-10·5 g/dL at enrolment, and who had between one and ten vaso-occlusive crisis events in the previous 12 months were enrolled. Patients receiving regularly scheduled transfusion therapy, who had received a transfusion in the previous 60 days, or who had been admitted to hospital for a vaso-occlusive crisis in the previous 14 days were excluded. Patients were randomly assigned (1:1:1) to receive either once-daily oral voxelotor 1500 mg, voxelotor 900 mg, or placebo for 72 weeks. Randomisation was done centrally by use of an interactive web response system, stratified by baseline hydroxyurea use (yes vs no), age group (adolescents [12 to <18 years] vs adults [18 to 65 years]), and geographic region (North America vs Europe vs other). The primary endpoint (already reported) was the proportion of patients who achieved a haemoglobin response at week 24. In this final analysis, we report prespecified long-term efficacy assessments by intention to treat, including changes in haemoglobin concentrations from baseline to week 72, changes in the concentration of haemolysis markers (absolute and percentage reticulocytes, indirect bilirubin concentrations, and lactate dehydrogenase concentrations) from baseline to week 72, the annualised incidence of vaso-occlusive crises, and patient functioning, as assessed with the Clinical Global Impression of Change (CGI-C) scale. Safety was assessed in patients who received at least one dose of treatment (modified intention-to-treat population). This trial is registered with ClinicalTrials.gov, NCT03036813.

FINDINGS: Between Dec 5, 2016, and May 3, 2018, 449 patients were screened, of whom 274 were randomly assigned to the voxelotor 1500 mg group (n=90), the voxelotor 900 mg group (n=92), or the placebo group (n=92). At week 72, the adjusted mean change in haemoglobin concentration from baseline was 1·0 g/dL (95% CI 0·7 to -1·3) in the voxelotor 1500 mg group, 0·5 g/dL (0·3 to -0·8) in the voxelotor 900 mg group, and 0·0 g/dL (-0·3 to 0·3) in the placebo group, with a significant difference observed between the voxelotor 1500 mg group and the placebo group (p<0·0001), and between the voxelotor 900 mg group and the placebo group (p=0·014). Significant improvements in markers of haemolysis, as assessed by the difference in adjusted mean percentage change from baseline at week 72 versus placebo, were observed in the voxelotor 1500 mg group in indirect bilirubin concentrations (-26·6% [95% CI -40·2 to -12·9]) and percentage of reticulocytes (-18·6% [-33·9 to -3·3]). The proportion of patients in the voxelotor 1500 mg group who were rated as "moderately improved" or "very much improved" at week 72 with the CGI-C was significantly greater than in the placebo group (39 [74%] of 53 vs 24 [47%] of 51; p=0·0057). Serious adverse events unrelated to sickle cell disease were reported in 25 (28%) of 88 patients in the voxelotor 1500 mg group, 20 (22%) of 92 patients in the voxelotor 900 mg group, and 23 (25%) of 91 patients in the placebo group. Grade 3 or 4 adverse events were infrequent (ie, occurred in <10% of patients); anaemia occurred in five or more patients (two [2%] patients in the voxelotor 1500 mg group, seven [8%] patients in the voxelotor 900 mg group, and three [3%] patients in the placebo group). Of all 274 patients, six (2%) deaths occurred during the study (two deaths in each treatment group), all of which were judged as unrelated to treatment.

INTERPRETATION: Voxelotor 1500 mg resulted in rapid and durable improvements in haemoglobin concentrations maintained over 72 weeks and has potential to address the substantial morbidity associated with haemolytic anaemia in sickle cell disease.

FUNDING: Global Blood Therapeutics.

Ghallab, M. A., M. E. M. Batanouny, A. A. Abd-Elhady, and I. M. Youssef, "Volume Incentive Spirometer is more Effective than Flow Incentive Spirometer on Arterial Blood Gases in Patients with Pneumonia", Journal of Cardiovascular Disease Research, vol. 12, issue 6, pp. 102-110, 2021. dr_esraa.pdf
Hossam Moftah, Walaa Elmasry, N. Ghali, A. E. Hassanien, and M. Showman, "Volume Identification and Estimation of MRI Brain Tumor.", The IEEE International Conference on Hybrid Intelligent Systems (HIS2012)., Pune. India, 4-7 Dec. 2012, , pp. 120 - 124, 2012. Abstract

This paper deals with two dimensional magnetic resonance imaging (MRI) sequence of brain slices which include many objects to identify and estimate the volume of the brain tumors. More than twenty five features based on shape, color and texture was extracted to obtain feature vector for each object to characterize the tumor and identify it. Experimental results show that the accuracy of the estimation of tissue volumes is very high.

Moftah, H. M., N. Ghali, A. E. Hassanien, M. A. Ismail, and others, "Volume identification and estimation of MRI brain tumor", Hybrid Intelligent Systems (HIS), 2012 12th International Conference on: IEEE, pp. 120–124, 2012. Abstract
n/a
Moftah, H. M., N. I. Ghali, A. E. Hassanien, and M. A. Ismail, "Volume identification and estimation of MRI brain tumor", Hybrid Intelligent Systems (HIS), 2012 12th International Conference on: IEEE, pp. 120–124, 2012. Abstract
n/a
Grace, S. R., and B. S. Lalli, "Volume 187, Number 1 (1994): Oscillation Theorems for Forced Neutral Difference Equations, pp. 91-106", Journal of Mathematical Analysis and Applications, vol. 198, issue 3: New York, Academic Press., pp. 922-922, 1996. Abstract
n/a
Galal, A., H. K. Hassan, and N. F. Atta, "Voltammetric Study of the Electrocatalytic Oxidation of Formaldehyde on Pt- Pd Co-catalyst Supported on Reduced Graphene Oxide", Electroanalysis, vol. 32, pp. 2733 – 2744, 2020.
Saad, A. S., A. M. Abou Al-Alamein, M. M. Galal, and H. E. Zaazaa, "Voltammetric determination of lidocaine and its toxic metabolite using C18 silica modified carbon paste electrode", Journal of the Electrochemical Society, vol. 166, issue 2, pp. B103-B109, 2019. Abstract

n/a

Saad, A. S., A. A. M. Al-Alamein, M. M. Galal, and H. E. Zaazaa, "Voltammetric Determination of Lidocaine and Its Toxic Metabolite in Pharmaceutical Formulation and Milk Using Carbon Paste Electrode Modified with C18 Silica", Journal of the Electrochemical society, vol. 166, issue 2, pp. 103-109, 2019.
Saad, A. S., A. A. M. Al-Alamein, M. M. Galal, and H. E. Zaazaa, "Voltammetric Determination of Lidocaine and Its Toxic Metabolite in Pharmaceutical Formulation and Milk Using Carbon Paste Electrode Modified with C18 Silica", Journal of The Electrochemical Society, vol. 166(2), 2019.
Al-Alamein, A. A. M., A. S. Saad, M. M. Galal, and H. E. Zaazaa, "Voltammetric Determination of Lidocaine and Its Toxic Metabolite in Pharmaceutical Formulation and Milk Using Carbon Paste Electrode Modified with C18 Silica", Journal of The Electrochemical Society,, vol. 166 , issue 2, pp. B103-B109, 2019.
Atta, N. F., A. Galal, and R. A. Ahmed, "Voltammetric Behavior and Determination of Isoniazid Using PEDOT Electrode in Presence Of Surface Active Agents", Int. J. Electrochem. Sci. 6: 5097 - 5113 (2011) IF:2.808, vol. 6, pp. 5097-5113, 2011. AbstractCU-PDF.pdf

An electrochemical sensor was developed by using poly (3,4-ethylenedioxy thiophene) electrode in presence of different types of surfactants. Voltammetric behavior of isoniazid was studied at this electrode in the presence and absence of SDS and CTAB and interesting electrocatalytic effects were found. The presence of surfactant in the medium plays a key role in the electrostatic attraction and repulsion of isoniazid towards the polymeric surface in different pH values. The electrochemical behavior of isoniazid was investigated by cyclic voltammetry, linear sweep voltammetry (LSV), and electrochemical impedance spectroscopy (EIS). The linear response obtained for isoniazid was in the range of 0.1 to 8 ?mol L-1 and 10 to 100 ?mol L-1 with correlation coefficients of 0.999 and 0.998 and detection limits 32 nmol L-1 and 45 nmol L-1, respectively. The utility of this modified electrode was demonstrated for the determination of INH in human urine.

Ghobashy, R. H., M. M. Ismail Ali, and M. A. M. Hassan, "Voltage Regulation of PV System Connected to Grid Based on FOPID Controllers Using Evolutionary Computational Techniques", 2018 20th International Middle East Power Systems Conference, MEPCON 2018 - Proceedings, pp. 33-38, 2019. Abstract
n/a
Hanafy, H. H., A. M. Gesraha, M. M. Abd-Elaziz, and A. F. Zobaa, "Voltage and Frequency Control of Self-Excited Short-Shunt Induction Generator", Journal of Engineering and Computer Sciences, Qassim University, vol. 1, issue 2, pp. 95-108, 2008.
Hafez, O., and H. Gindi, Voices of / from Africa, , Cairo, Cairo University Press, 2018.
El-Sayed, A., G. Ashour, M. Khalifa, and A. Gad, "Vitrification assessment of buffalo (Bubalus bubalis) oocytes: morphological and molecular aspects", Egyptian J. Anim. Prod, vol. 52, pp. 1-7, 2015. Abstract
n/a
Abdelkawi, S. A., A. M. Abdel-Salam, D. F. Ghoniem, and S. K. Ghaly, "Vitreous Humor Rheology After Nd:YAG Laser Photo Disruption", Cell Biochem Biophys, pp. 267-274, 2014. Abstractvitreous_humor_rheology_after_ndyag_laser_photo_disruption.pdf

Abstract This work aimed to consider the hazardous side effect of eye floaters treatment with Q-switched Nd:YAG laser on the protein and viscoelastic properties of the vit- reous humor, and evaluate the protective role of vitamin C against laser photo disruption. Five groups of New Zealand rabbits were divided as follows: control group for (n = 3) without any treatment, the second group (n = 9) treated with Q-switched Nd:YAG laser energy of 5 mJ 9 100 pulse delivered to the anterior, middle, and posterior vit- reous, respectively (n = 3 for each). The third group (n = 9) received a daily dose of 25 mg/kg body weight vitamin C for 2 weeks, and then treated with laser as the previous group. The fourth group (n = 9) treated with 10 mJ 9 50 pulse delivered to the anterior, middle, and posterior vitreous, respectively (n = 3 rabbits each). The fifth group (n = 9) received a daily dose of 25 mg/kg body weight vitamin C for 2 weeks, and then treated with laser as the previous group. After 2 weeks of laser treatment, the protein content, refractive index (RI), and the rheological properties of vitreous humor, such as consistency, shear stress, and viscosity, were determined. The results showed that, the anterior vitreous group exposed to of 5 mJ 9 100 pulse and/or supplemented with vitamin C, showed no obvious change. Furthermore, all other treated groups especially for mid-vitreous and posterior vitreous humor showed increase in the protein content, RI and the viscosity of vitreous humor. The flow index remained below unity indicating the non-Newtonian behavior of the vitreous humor. Application of Q-switched Nd:YAG laser should be restricted to the anterior vitreous humor to prevent the deleterious effect of laser on the gel state of the vitreous humor.

Keywords Consistency · Flow index · Refractive index ·

Total protein · Viscosity · Vitamin C

Abu Eleinen, K. G., A. A. Mohalhal, D. A. Ghalwash, A. A. Abdel-Kader, A. A. Ghalwash, I. A. Mohalhal, and A. M. Abdullatif, "Vitrectomy with scleral buckling versus with inferior retinectomy in treating primary rhegmatogenous retinal detachment with PVR and inferior breaks.", Eye (London, England), vol. 32, issue 12, pp. 1839-1844, 2018. Abstract

PURPOSE: To evaluate anatomic and functional outcomes of patients treated with pars plana vitrectomy (PPV) with scleral buckling versus PPV with inferior retinectomy for treatment of cases of primary rhegmatogenous retinal detachment (RRD) associated with proliferative vitreoretinopathy (PVR) and inferior retinal breaks.

METHODS: Retrospective, comparative, interventional, single-center study. Fifty-one eyes of fifty-one patients with primary RRD associated with inferior breaks and PVR grade C1 or more were reviewed over 3 years. Twenty-one eyes underwent PPV with encircling band 360° and thirty eyes underwent PPV with primary inferior retinectomy. The primary outcome was final anatomic success. Secondary outcomes included change in visual acuity, primary anatomical success, the mean number of operations, and incidence of postoperative complications.

RESULTS: Primary anatomical success of 85.7% was achieved in buckle group compared to 83.3% in retinectomy group (p = 0.82). Mean duration of follow-up and mean number of operations was 9.8 ± 2.26 and 9.97 ± 2.44 months; 1.24 ± 0.62 and 1.3 ± 0.75 in buckle group and retinectomy group, respectively, achieving final anatomical success of 95.2% for the buckle group and 90% for the retinectomy group with no statistical significant difference (p = 0.49). Although visual acuity (logMAR) was better in the buckle group in the 1st month, it became nearly equal thereafter during the follow-up period (p = 0.5).

CONCLUSION: Similar anatomical and functional outcomes were achieved by combining PPV with scleral buckle or inferior retinectomy for treatment of primary RRD with PVR and inferior breaks.

Elnahry, A. G., E. M. Sallam, K. J. Guirguis, J. H. Talbet, and A. A. Abdel-Kader, "Vitrectomy for a secondary epiretinal membrane following treatment of adult-onset Coats' disease.", American journal of ophthalmology case reports, vol. 15, pp. 100508, 2019. Abstract

Purpose: To report a case of adult-onset Coats' disease that had worsening of macular edema and progressive macular traction following cryotherapy and repeated intravitreal bevacizumab injections due to formation of a secondary epiretinal membrane which only improved following pars plana vitrectomy and membrane peeling.

Observations: A 35-year-old male presented with diminution of vision in his left eye and was found to have localized telangiectatic retinal vessels and aneurysmal dilatations with massive exudation and cystoid macular edema. He was diagnosed as adult-onset Coats' disease and treated with cryotherapy and a concomitant intravitreal injection of 2.5 mg bevacizumab followed by 3 monthly intravitreal injections of 2.5 mg bevacizumab and a single injection of 4 mg triamcinolone acetonide. Partial obliteration of the telangiectatic vessels and aneurysmal dilatations with improvement in surrounding lipid and fluid exudate was achieved, however, this was associated with progressive worsening of macular edema and macular traction due to formation of an epiretinal membrane which only improved following vitrectomy and membrane peeling. Effect of therapy at each stage was evaluated using visual acuity testing, fundus examination, fundus fluorescein angiography, and optical coherence tomography.

Conclusion and Importance: A secondary epiretinal membrane can develop following treatment of adult-onset Coats' disease and cause traction especially when combining cryotherapy with bevacizumab injections. Vitrectomy in such cases with membrane peeling may result in improvement of anatomical and functional outcomes.

Gramoun, A., M. F. Manolson, J. N. M. Heersche, D. P. Trebec, and S. Y. Mao, "Vitaxin (R), an alphav beta3 blocking antibody, inhibits osteoclastic resorption by decreasing the number of attached osteoclasts.", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 19: AMER SOC BONE & MINERAL RES 2025 M ST, NW, STE 800, WASHINGTON, DC 20036-3309 USA, pp. S154–S154, 2004. Abstract
n/a